# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Andrew Fein reiterates Kymera Therapeutics (NASDAQ:KYMR) with a Buy and maintains $46 price ...
KT-253 demonstrates initial clinical proof of concept in patients with tumor types shown to be sensitive in preclinical model...
HC Wainwright & Co. analyst Andrew Fein reiterates Kymera Therapeutics (NASDAQ:KYMR) with a Buy and maintains $46 price ...
Jared Gollob, MD, Chief Medical Officer, Kymera Therapeutics, said "We look forward to sharing the full Phase 1 data set, ...
KT-621, a potent, selective, oral STAT6 degrader, demonstrated comparable or superior activity to dupilumab in preclinical stud...
Abstract released today highlights safety, pharmacodynamic and clinical response data collected through February 6, 2024 cut-of...
Oppenheimer analyst Jeff Jones maintains Kymera Therapeutics (NASDAQ:KYMR) with a Outperform and lowers the price target fro...
Kymera Therapeutics (NASDAQ:KYMR) reported quarterly losses of $(0.69) per share which beat the analyst consensus estimate of $...